200 related articles for article (PubMed ID: 32763140)
21. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
22. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
23. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
[TBL] [Abstract][Full Text] [Related]
24. C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors.
Franceschini C; Trapella C; Calia R; Scotti A; Sforza F; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1034-9. PubMed ID: 22871133
[TBL] [Abstract][Full Text] [Related]
25. Application of two direct C(sp3)-H functionalizations for total synthesis of (+)-lactacystin.
Yoshioka S; Nagatomo M; Inoue M
Org Lett; 2015 Jan; 17(1):90-3. PubMed ID: 25526222
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
27. Insight into Inhibitor Binding in the Eukaryotic Proteasome: Computations of the 20S CP.
Hodošček M; Elghobashi-Meinhardt N
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30514002
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
30. Pseudopeptides with aldehyde or vinylsulfone warheads: Synthesis and antiproteasomal activity.
Jorda R; Molitorová V; Pilařová E; Vojáčková V; Řezníčková E; Svobodová K; Pauk K; Imramovský A; Kryštof V
Bioorg Chem; 2021 Oct; 115():105228. PubMed ID: 34371374
[TBL] [Abstract][Full Text] [Related]
31. Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.
Artschwager R; Ward DJ; Gannon S; Brouwer AJ; van de Langemheen H; Kowalski H; Liskamp RMJ
J Med Chem; 2018 Jun; 61(12):5395-5411. PubMed ID: 29782167
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
33. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
34. Development of novel proteasome inhibitors based on phthalazinone scaffold.
Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a potent and highly specific β
Zhou T; Cai Y; Liang L; Yang L; Xu F; Niu Y; Wang C; Zhang JL; Xu P
Bioorg Med Chem Lett; 2016 Dec; 26(23):5780-5784. PubMed ID: 27816516
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
[TBL] [Abstract][Full Text] [Related]
37. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
38. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
[TBL] [Abstract][Full Text] [Related]
39. Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.
Yoo E; Stokes BH; de Jong H; Vanaerschot M; Kumar T; Lawrence N; Njoroge M; Garcia A; Van der Westhuyzen R; Momper JD; Ng CL; Fidock DA; Bogyo M
J Am Chem Soc; 2018 Sep; 140(36):11424-11437. PubMed ID: 30107725
[TBL] [Abstract][Full Text] [Related]
40. Nostocyclopeptides as New Inhibitors of 20S Proteasome.
Fidor A; Cekała K; Wieczerzak E; Cegłowska M; Kasprzykowski F; Edwards C; Mazur-Marzec H
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
